ArticleGut and liver2021
Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for
Article in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Guideline
- 14-day Empirical Therapy Compared with 7-day Tailored Therapy forYonsei medical journal · 2026Trial
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026Article
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Transcriptomic and Molecular Insights into the Response of Multidrug-Resistant Helicobacter pylori to Human Neutrophil Peptide 1 (HNP-1).Probiotics and antimicrobial proteins · 2026Article
- Detection of Clarithromycin Resistance in Helicobacter pylori Using the AllplexTM H. pylori & ClariR Assay and the Ezplex® HP-CLA Real-Time PCR Kit.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment ofTherapeutic advances in gastroenterology · 2025Article
- Detection of Clarithromycin Resistance in Helicobacter pylori Using MmaxSure™ H. pylori & ClaR Assay.Digestive diseases (Basel, Switzerland) · 2024Article
- Types of 23S Ribosomal RNA Point Mutations AffectingThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility ofGut and liver · 2023Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- [Eradication ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance.BMC microbiology · 2023Article
- Article
- Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication ofFrontiers in medicine · 2023Article
- Current guidelines forWorld journal of clinical cases · 2022Review
- Benefits of a Molecular-Based Method for the Detection of Clarithromycin-ResistantGut and liver · 2021Article
- Characteristics ofFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Methods: We retrospectively investigated a total of 464 consecutive patients who underwent an endoscopic examination and dual-priming oligonucleotide-based multiplex polymerase chain reaction for Results: The eradication rates of standard triple and bismuth-quadruple therapies showed no significant difference in mutation-negative patients or those with the A2142G point mutation. However, the eradication rate with bismuth-quadruple therapy was significantly higher than that with standard triple therapy in the group with the A2143G mutation or with the double mutation. The eradication rates for standard triple and bismuth-quadruple therapies, respectively, were 25.8% and 92.1% in the per-protocol group (p<0.001) and 24.2% and 85.2% in the intention-totreat analysis (p<0.001). Conclusions: The A2143G point mutation is the most prevalent cause of clarithromycin resistance. Bismuth-quadruple therapy is superior to standard triple therapy in patients with the A2143G or double point mutation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.